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Abstract
Background: Vaginal probiotics are investigated as a binary strategy for prevention of bacterial vaginosis and HIV.
We applied an innovative experimental model using primary and immortalized human cervical and vaginal
epithelial cells to assess the functional properties of Lactobacillus jensenii, a predominant constituent of the healthy
vaginal microbiome, engineered to express the HIV-1 entry inhibitor modified cyanovirin-N (mCV-N). In this model
bacteria colonize the epithelial cells over a period of 24-72 h. Staurosporine and the Toll-like receptor 2/6 ligand
macrophage-activating lipopeptide-2 (MALP-2) serve as positive controls for apoptosis and proinflammatory
activation, respectively. In 24-hour intervals, the colonized epithelium is assessed microscopically, supernatants are
collected for measurement of soluble immunoinflammatory mediators and production of CV-N, and cells are lysed
for assessment of: 1) apoptosis by cleaved versus total caspase-3 assay; 2) NF-κB activation by a luciferase reporter
assay; or 3) epithelia-associated colony forming units (CFU) in Brucella agar.
Results: Wild type (WT) L. jensenii 1153 consistently colonized cervical and vaginal cells in the absence of epithelial
damage and apoptosis. The bioengineered derivatives expressing mCV-N or control plasmids showed the same
stable colonization pattern, which was reproducible between technologists and bacterial batches (CFU coefficient
of variation <10% within and between experiments and epithelial cell types). MALP-2 activated NF-κB and caused
fold-increased levels of proinflammatory mediators with clinically established significance in the cervicovaginal
environment (IL-1α, IL-1β, IL-6, TNF-α, IL-8, RANTES, MIP-3α, and ICAM-1), measured by a multiplex
electrochemiluminescence assay. At the same time levels of protective anti-inflammatory mediators interleukin 1
receptor antagonist (IL-1RA) and secretory leukocyte protease inhibitor (SLPI), both measured by ELISA, remained
constant (IL-1RA) or moderately increased (SLPI). Similarly to MALP-2, colonization by L. jensenii WT activated NF-κB;
however, unlike the synthetic TLR2/6 ligand, the live microorganisms did not induce significant changes in the
secreted levels across all inflammation-associated proteins. The mCV-N production and function were confirmed by
western blot and a HIV-1 gp120 binding assay, respectively. The bioengineered lactobacilli expressed mCV-N with
anti-HIV activity preserved in the epithelial cell context and caused no significant immunoinflammatory changes as
compared to the WT L. jensenii.
Conclusions: These results highlight the translational value of the colonization model and justify further clinical
investigation of the homeostatic and anti-HIV effectiveness of the L. jensenii derivates.
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Topical microbicides have been investigated as a leading
prevention strategy in the HIV/AIDS pandemic, which
currently affects 34 million people around the globe [1].
A number of compounds with broad-spectrum anti-HIV
activity in-vitro have successfully passed preclinical
and Phase I evaluations, nevertheless, those selected for
Phase II/III trials have failed to prevent HIV thus far
[2-6]. Anti-retrovirals with more specific anti-HIV activ-
ities have also been explored; however, tenofovir, the
only topical gel candidate tested in Phase II/III settings
as of yet, had initially demonstrated marginal (39%)
effectiveness [7], but has most recently been disconti-
nued due to futility [8].
The impracticality and numerous pharmacokinetic
difficulties of the coitally- related dosing strategy are
shortcomings of the conventional gel-based microbicides
[2,3,7,9,10]. Gels may not efficiently cover the entire
genital tract mucosal surface vulnerable to HIV entry.
Typically gels require application shortly before inter-
course to be protective and frequently may require
re-application to counter the effects of dilution, degrad-
ation or rapid clearance [11]. On the other hand,
frequent exposure of the vaginal environment to foreign
substances can have toxic effects and damage the epithe-
lial membranes resulting in irritation and undesirable
inflammatory responses increasing the risk of HIV ac-
quisition [12]. A solution to these shortcomings may be
offered by bioengineered probiotic products based on
vaginal/rectal commensal organisms that are capable of
delivering anti-HIV factors in a sustainable, non-inflam-
matory, self-renewing mechanism directly at the point of
viral infection [13-19].
This study applied an innovative experimental model
of microbiota colonized epithelium [20] to assess the
immunoinflammatory properties of a probiotic-based
anti-HIV microbicide. Osel, Inc (Mountain View, CA)
has genetically engineered Lactobacillus jensenii, one of
the predominant components of the normal vaginal
microbiota [21,22], to express a modified version of the
anti-HIV Cyanobacterium protein Cyanovirin-N (mCV-
N) [15]. The natural CV-N protein interrupts HIV-1
membrane fusion by impairing CD4 independent and
dependent binding of gp120 to the HIV-1 co-receptors
CCR5 and CXCR4 [23,24]. Pusch et al. demonstrated
HIV-1 inhibition in-vitro with another modified version
of CV-N expressed by L. plantarum and Lactococcus
lactis [16]. The bioengineered mCV-N invented by Osel
Inc. irreversibly inactivates both CXCR4 and CCR5
tropic HIV strains in-vitro [15,23]. L. jensenii expressing
mCV-N at concentrations of 7×10
8 CFU/ml, mimicking
the natural L. jensenii concentrations found in women
[25], completely inhibited CCR5 tropic HIV-1 entry in-
vitro [15,26]. Both the natural CV-N and mCV-N are
inhibitory against T-tropic, M-tropic and dual T and M-
tropic primary clinical strains of HIV-1 and T-tropic la-
boratory adapted strains of HIV-1 and HIV-2 in-vitro
[15,23]. L. jensenii 1153 was selected as a parental strain
due to it’s growth, colonization rates and inherent pro-
biotic properties [15]. Our study is the first to assess
simultaneously the colonization and immunomodulatory
properties of 1153 and its mCV-N producing derivatives
in the human vaginal epithelial cell context. Hereby we
tested the hypotheses that: 1) an in-vitro model can
mimic key components of the microbiota-epithelial
interactions in a sustained reproducible manner allowing
comparison of multiple bioengineered strains, 2) genet-
ically engineered L. jensenii strains can deliver a bio-




The parental wild type (WT) L. jensenii 1153 human va-
ginal isolate and five experimental derivatives (Table 1)
were obtained from Osel, Inc (Mountain View, CA). The
generation of the bioengineered strains was previously
published [15].
Control test agents
The synthetic macrophage-activating lipopeptide-2
(MALP-2) (Alexis Biologicals, San Diego, CA), a known
Toll-like receptor (TLR) 2/6 ligand, was used at 50 nM
as a pro-inflammatory control [20,27]. Staurosporine
(Sigma-Aldrich, St. Louis, MO) was used at 1 μMa sa
pro-apoptotic agent [20,28,29].
Epithelial models
Human immortalized endocervical (End1/E6E7) and va-
ginal (Vk2/E6E7) epithelial cell lines were grown in
antibiotic-free keratinocyte serum-free medium (KSFM)
(Invitrogen, Carlsbad, CA) supplemented with bovine pi-
tuitary extract, epidermal growth factor and calcium
chloride as described [30]. These immortalized cell lines
have been previously shown to closely resemble the col-
umnar (End1/E6E7) and stratified squamous (Vk2/E6E7)
epithelial differentiation patterns and immune responses
of primary cells and normal tissues of origin [30-36].
Polarized tissue constructs VEC-100
™ derived from pri-
mary ectocervical/vaginal epithelial cells, previously
depicted immune properties comparable to that of nor-
mal tissues of origin [37,38] were purchased from
MatTek Corporation, Ashland, MA. The VEC-100
™
tissues were maintained in antibiotic-free medium pro-
vided by MatTek.
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bioengineered derivatives
Multiple aliquots from three separate batches of L. jense-
nii WT and derivatives were received frozen from Osel,
Inc and stored at −80°C until tested. Each batch was
examined in a minimum of three independent experi-
ments. All strains were tested simultaneously by com-
parison of colony forming units (CFU) before use in our
epithelial colonization model. For that purpose, one
aliquot per strain from each batch was thawed, washed
once in PBS by centrifugation, serially diluted in PBS
and plated onto Brucella-based agar plates (PML Micro-
biologicals, Wilsonville, OR). Plates were incubated in an
anaerobic chamber (Coy Laboratory Products Inc., Grass
Lake, MI) containing an atmosphere of 10% carbon
dioxide, 10% hydrogen, 80% nitrogen at 37°C for 24 h-48 h
(until visible colonies formed), followed by CFU counting.
Percent recovery of viable bacteria was determined in
comparison to CFU counts obtained prior to cryopreser-
vation by Osel, Inc.
Epithelial colonization
L. jensenii suspensions were prepared in antibiotic-free
KSFM (Invitrogen) at 7×10
6 CFU/ml to colonize epithe-
lial surfaces for 24 h, 48 h and 72 h as previously
described for other vaginal bacteria [20]. In the immor-
talized cell line model, epithelial monolayers were grown
to 100% confluence in 96-well plates (Fisher Scientific,
Pittsburgh, PA) and bacterial suspensions (0.1 ml) were
added to achieve a multiplicity of infection of ~10:1. In
the VEC-100
™ model, tissue inserts were placed over
0.5 ml medium in 12-well plates (Fisher Scientific)
followed by addition of 0.156 ml bacterial suspension to
the apical epithelial surface. The bacterial-epithelial
cocultures were incubated for 24 h-72 h under anaerobic
conditions generated by AnaeroPack System (Mitsubishi
Gas Chemical Co. Inc., New York, NY), at 35°C on an
orbital shaker. Cell culture supernatants from the
immortalized epithelia and basal chamber culture fluids
from the VEC-100 tissue model were collected in 24 h
time intervals for measurement of soluble immune
mediator levels and mCV-N as described below. At the
end of each 24 h period the cells/tissue were washed
and used for enumeration of epithelia-associated CFU
(see below), or medium was reapplied and cultures were
returned to anaerobic chamber for additional 24 h incu-
bations. In some experiments, the cells were lysed for
assessment of NF-κB activation or apoptosis (see sec-
tions below).
Transmission electron microscopy
Vk2/E6E7 cells were seeded on Aclar embedding film
(Ted Pella Inc. Redding CA) and colonized with L. jensenii
strains for 24 h. A TecnaiG2 Spirit BioTWIN transmission
electron microscope (FEI Company, Hillsboro, OR) was
used to visualize bacterial-epithelial colonization, confirm
morphological integrity and a lack of apoptosis as previ-
ously described [20].
Epithelium-associated CFU enumeration
Association of viable lactobacilli with epithelial cells was
assessed by CFU counts as described in detail elsewhere
[20]. In brief, at the end of each time period, the cultures
were washed twice with ice-cold PBS and hypotonically
lysed for 15 min in ice-cold HyPure water (Fisher Scien-
tific), followed by adjustment of osmolarity with 2×
concentrated PBS (Invitrogen). Serial dilutions were pre-
pared in PBS and 30 μl of each dilution was inoculated
on Brucella-based agar plates (PML Microbiologicals).
The plates were incubated in an anaerobic chamber
(Coy Laboratory Products Inc) containing an atmos-
phere of 10% hydrogen, 10% carbon dioxide and 80%
nitrogen at 37°C for 24 h-48 h (until visible colonies
were formed), followed by CFU counting. CFU per cm
2
epithelial surface area were calculated.
NF-κB activation luciferase reporter assay
Endocervial epithelial cells stably transfected with pHTS-
NF-κB firefly luciferase reporter vector (Biomyx Techno-
logy, San Diego, CA) as described [34] were grown in
96-well plates in hygromycin selection medium until con-
fluence and then colonized with L. jensenii strains as
Table 1 Bioengineered L. jensenii derivatives with the expression cassette stably integrated into the bacterial
chromosome





L. jensenii 1153-1666 pox1 rpsU APVT-CV-N (P51G)
L. jensenii 1153-2666 pox1 ptsH APVT-CV-N (P51G)
L. jensenii 1153-3666 pepO rpsu APVT-CV-N (P51G)
L. jensenii 1153-1646 pox1 gusA Gus A (β-glucoronidase)
L. jensenii 1153-GFP pox1 rpsU EGFP
c
aParental L. jensenii strain
;b NA=not applicable (wild type strain);
cenhanced green fluorescent protein.
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cells were lysed with GloLysis buffer and luciferase activity
was determined using the Bright-Glo Luciferase Assay
System by manufacturer’s protocol (Promega, Madison,
WI).
Caspase-3 assay
Vaginal epithelial cells (Vk2/E6E7) were treated with
bacteria, MALP-2 (50 nM) and the proapoptotic agent
staurosporine (1 μM) to serve as a positive control. At
the end of each incubation period, the epithelial mono-
layers were lysed in Tris lysis buffer containing protease
inhibitor cocktail provided by Mesoscale Discovery
(MSD), Gaithersburg, MD, per manufacturer’s protocol.
Levels of cleaved and total caspase-3 were measured
simultaneously in each cell lysates using an MSD elec-
trochemiluminescence (ECL) mutliplex assay and Sector
Imager 2400 with Workbench software (MSD).
Soluble immune mediators assays
Concentrations of interleukin (IL-1α, IL-1β, IL-6, TNF-
α, IL-8, RANTES, MIP-3α, and ICAM-1) were measured
in cell culture supernatants simultaneously using an
MSD multiplex assay, Sector Imager 2400, and Work-
bench software. Levels of IL-1 receptor antagonist (IL-
1RA) and the antimicrobial peptide secretory leukocyte
protease inhibitor (SLPI) were measured by Quantikine
ELISA (R&D Systems, Minneapolis, MN) using a Victor
2
reader (Perkin Elmer Life Sciences, Boston, MA).
mCV-N detection and functional recovery
Cell culture supernatants collected from the vaginal and
cervical colonization models were sterilized through 0.2
micron PharmAssure’s Low protein binding syringe fil-
ters with HT Tuffryn Membrane (Pall Corporation, Port
Washington, NY). Western blot analysis of the filtered
supernatants was performed as described [13] to ensure
full length expression of CV-N in the experimental
model, and to rule out loss of protein to filtration. The
filtered sterile supernatants were subjected to a gp120
binding assay to confirm the presence of functional
mCV-N in the epithelial context. In brief, 96-well plates
(Aalto Bio, Dublin, Ireland) coated with anti-HIV-1
gp120 antibody bound to recombinant gp120 (Protein
Sciences, Meriden, CT) were incubated with undiluted
cell culture supernatants for 2 h to allow for gp120 bin-
ding. Bound molecules were detected by rabbit anti-
mCV-N and anti-rabbit horseradish peroxidase (HRP)
(Alpha Diagnostics, San Antonio, TX) as described [13].
Statistical analysis
One-way ANOVA with Bonferroni multiple comparisons
analysis were performed using GraphPad Prism version
4.00 for Windows (GraphPad Software, San Diego CA).
P values <0.05 were considered significant.
Results
L. jensenii reproducibly and consistently associates with
the primary and immortalized cervicovaginal epithelial
cells in the absence of apoptosis
Both parental and experimental strains of L. jensenii
1153 colonized morphologically intact epithelial cell
monolayer observed by light microscopy at the end of
each time period. Transmission electron microscopic
images were obtained 24 h post colonization (Figure 1a).
The lack of bacteria-induced apoptosis in our model was
confirmed by assessment of cleaved versus total caspase
3, showing significant increases of cleaved caspase 3 only
by the staurosporine control (Figure 1b).
Figure 1 Lactobacillus strains consistently associate with the
human epithelial model in the absence of apoptosis. (Figure 1a)
Transmission electron microscopic image illustrates clear association
between the L. jensenii electron dense bodies and the
morphologically intact vaginal epithelial cells. No morphological
signs of apoptosis are present. Bar represents 2 microns with a
magnification of x 4800. (Figure 1b) Caspase-3 cleavage represented
by % cleaved over total caspase harvested from vaginal (Vk2/E6E7)
epithelial lysates after 24 h colonization with L. jensenii 1153 wild
type (WT) and bioengineered L. jensenii 1153–1666, 3666 and gfp
strains or treatment with 1 μM Staurosporine positive control. Bars
display means and SEM from triplicate cultures in one of three
experiments. ** P<0.01 different from medium control.
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very from frozen bacterial stocks measured by CFU. No
variation was found due to performing technicians or dilu-
tions in multiple bacteria batches tested (Figure 2a).
Wild type L. jensenii and all bioengineered derivatives
reproducibly generated similar epithelial cell associated
CFU counts. Comparable results were obtained with the
primary polarized/stratified VEC-100 tissue model as with
the immortalized cervical and vaginal epithelial monolayer
models. These results were confirmed by comparable
colonization rates in multiple experiments with two separ-
ate batches of WTand bioengineered bacteria (Figure 2b).
Wild type and bioengineered L. jensenii strains induced
NF-κB activation but not proinflammatory protein
production
In order to compare the proinflammatory potential of the
WTand derivative bacterial strains, we first examined their
effects on the endocervical epithelial cell line stably trans-
fected with the NF-κB-driven luciferase reporter gene in
the first 24 h of bacterial-epithelial coculture. Luciferase
was measured in cell lysates and IL-8 and SLPI were mea-
sured in the paired cell culture supernatants from the same
cultures. All bacterial strains caused NF-κB driven lucifer-
ase activity similar to that induced by the TLR2/6 ligand
MALP-2 (Figure 3a) at significantly (P<0.001) higher levels
than the sterile medium control (~4-fold increase). How-
ever, only MALP-2 induced a significant (P<0.01) IL-8
increase (>30-fold) as compared to the medium (no bac-
teria) control (Figure 3b). MALP-2 alone induced a signifi-
cant (P<0.05) although moderate (<2-fold) increase in SLPI
levels measured in the same endocervical cultures as com-
pared to the WT L. jensenii (Figure 3c). IL-8 and SLPI
levels were not significantly changed by colonization with
both the WTand mCV-N expressing bacteria as compared
to medium control.
To confirm these findings in the primary tissue model,
we treated VEC-100
™, Vk2/E6E7 and End1/E6E7 cells
simultaneously with medium, MALP-2, the WT and
bioengineered L. jensenii derivatives (Figure 4). Again,
MALP-2, in contrast to L. jensenii, induced a significant
IL-8 upregulation in all three models. Since the findings in
the primary tissue model (Figure 4a) mirrored those in the
immortalized epithelial monolayers (Figure 3b and 4b), as
previously reported with other vaginal bacteria [20], we
chose the immortalized cell line model for further analysis
of immunity mediators and CFU counts based on its lower
cost- and handling time efficiency.
In further immune mediator analysis of L. jensenii
colonized Vk2/E6E7 immortalized epithelial monolayers;
MALP-2 induced significant increases over baseline levels
of TNF-α (P<0.001) and IL-6 (P<0.001), while the WT
and derivatives had no significant effect on either
(Figure 5a-b). IL-1α levels slightly increased (P<0.05) in
the presence of the WT, however all derivatives main-
tained baseline levels (Figure 5c). No significant diffe-
rences were observed in IL-1RA levels (Figure 5D).
Sustained bacterial colonization by wild type and
bioengineered L. jensenii does not alter levels of
inflammation-associated proteins over time
To determine if the homeostatic effect of L. jensenii on
innate immunity proteins is sustained over time, despite
Figure 2 Technical standardization elicits reproducible results
in colony forming units. L. jensenii 1153 wild type (WT) and
bioengineered L. jensenii 1153–1666, 2666, 3666 and 1646 strains
before and after coculture with vaginal and cervical epithelia.
(Figure 2a) Full recovery from frozen bacterial stocks and technical
reproducibility assessed by % recovery of log CFU in multiple
dilutions of quadruplicate cultures prior to epithelial coculture.
(Figure 2b) L. jensenii strains at 7x10
6 CFU/ml colonize vaginal (Vk2/
E6E7), primary (VEC-100
™) and immortalized (End1/E6E7) cervical
epithelia at a consistent rate in two separate batches of multiple
experiments. Bars represent mean and SEM of triplicate or
quadruplicate cultures.
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to wild type and bioengineered bacterial strains and
MALP-2 and maintained the cultures for three days with
supernatants harvested for protein measurement and
replaced with plain KSFM medium at each 24 h interval.
At the end of each 24 h time period epithelial cells were
lysed for assessment of epithelia-associated CFU. No sig-
nificant variation in CFU was observed in multiple
cultures of L. jensenii-colonized vaginal epithelial cells
over the extended period of 72 h (Figure 6a). The WT
and derivatives maintained steady baseline IL-8 levels at
24 h, 48 h, and 72 h with no significant differences
observed between the WT and bioengineered bacteria
(Figure 6b). As expected, MALP-2 increased IL-8 signifi-
cantly in the first 24 h time point as compared to both
medium control and wild-type colonized bacteria
(P<0.001), and after its removal at 24 h, the IL-8 levels
returned to normal the end of the 72 h period.
To determine if the lack of proinflammatory protein
upregulation over time is a broader phenomenon in the L.
jensenii colonized vaginal epithelium we expanded our
analysis using a multiplex MSD assay to quantify in the
same supernatants more mediators known to be asso-
ciated with the different steps of inflammatory cascades in
the female genital tract e.g. pro-inflammatory cytokines
IL-1β and IL-6, anti-inflammatory protective mediators e.
g. IL-1RA, adhesion molecules e.g. sICAM-1 and chemo-
kines MIP-3α and RANTES. As shown in Figure 7, neither
WT nor mCV-N expressing L. jensenii induced a signifi-
cant upregulation or down regulation of any of these med-
iators with the exception of ICAM-1 which was increased
in WT-colonized vaginal cells in the first 48 h only
(p<0.05) (Figure 7d). In contrast, MALP-2 induced a weak
upregulation of IL-1β (p<0.05) (Figure 7a), no change in
IL-1RA (Figure 7b) but a robust (several-fold) upregula-
tion (p<0.001) of IL-6, ICAM-1, MIP-3α and RANTES
(Figure 7c-f), and the chemokines remained increased for
48 h after MALP-2 removal (Figure 7e and f).
Expression of functional mCV-N expression and anti-HIV
activity is preserved in epithelia-associated L. jensenii
strains
Filtered sterile supernatants from 24 hL. jensenii colo-
nized vaginal and endocervical cells were assessed for
mCV-N recovery with western blot analysis on an SDS-
PAGE gel probed with anti-CV-N antibodies. All mCV-
N expressing strains (lanes 2–4; Figure 8a, lanes 4–5;
Figure 3 L. jensenii induced NF-κB expression without
immunogenic response. 24 h lysates and supernatants harvested
from endocervical (End1/E6E7) epithelial cells cultured with 7x10
6 L.
jensenii 1153 wild type (WT), bioengineered L. jensenii 1153–1666,
2666, 3666 and 1646 strains or MALP-2 (50 nM) as a positive control.
(Figure 3a) Luciferase activity measured in lysates from triplicate
cultures in one representative of five experiments. Bars represent
means and SEM ***P<0.001 different from medium control.
(Figure 3b) IL-8 production analyzed in corresponding supernatants,
bars are means and SEM from duplicate cultures in one
representative of 11 experiments **P<0.01 different from medium
control,
++P<0.01 different from L. jensenii WT. (Figure 3c) SLPI
detected in the same supernatants, bars are mean and SEM of
duplicate cultures in one representative of six experiments
+P<0.05
different from L. jensenii WT.
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a mCV-N standard (lane 1; Figure 8b). As expected, no
background binding to mCV-N was detected in cell cul-
ture supernatants derived from the MALP-2 or medium
controls (lanes 6–7; Figure 8a) or from either the WT
(lane 1; Figure 8a, lane 2; Figure 8b) or β-glucuronidase
producing strains (lane 5; Figure 8a, lane 6; Figure 8b).
No protein loss to filtration was observed when 1 μgo f
mCV-N standard was spiked in 1 ml of medium and
probed with anti-mCV-N antibody in a western blot pre
and post-filtration (Figure 8c).
Gp120 binding activity was measured in 24 h filtered
sterile supernatants from L. jensenii colonized cervical
and vaginal epithelial cells. Only the mCV-N producing
strain resulted in gp120 binding activity compared to the
WT and β-glucuronidase producing strains, MALP-2 or
medium control (Figure 8d). Data were replicated in
multiple experiments not shown here.
Discussion
Vaginal probiotics or live biotherapeutic products as
defined by the FDA [39] may reduce the risk of HIV
transmission by: expressing antiviral factors, restoring
the normal microbiota, inhibiting bacterial pathogens
and modulating immuno-inflammatory responses with-
out compromising the homeostatic environment of the
host. Lactobacilli are commensal Gram-positive bacteria
that widely populate the healthy female vaginal mucosa
[21,22,40,41]. Several Lactobacillus strains have been
implicated by epidemiologic and/or experimental evi-
dence in the maintenance of a homeostatic infection-
free microenvironment most notably due to the impact
of the bacteria’s lactic acid and H2O2 production in gen-
erating an adverse environment for HIV and other STDs.
[21,40,42-44]. These properties may contribute to the re-
duction of viral particles at the site of infection [13,45].
In contrast, a reduction in the number of Lactobacillus
in the vaginal microbiota has been associated with the
acquisition of bacterial vaginosis (BV) [42,45-47]. The
presence of BV is correlated with an increased risk of ac-
quiring herpes simplex virus type 2 [48], HIV and other
STDs [46,49]. In turn, co-infection with sexually trans-
mitted pathogens is associated with an increased risk of
acquiring and transmitting HIV [50,51]. Naturally occur-
ring lactobacilli demonstrate an inverse relationship with
HIV infectivity [44,45]. Sha et al. found an inverse ratio
between indigenous Lactobacillus counts and HIV RNA
detected in cervical vaginal lavage at nearly significant
levels [46]. In another study, L. jensenii demonstrated a
reduction in HIV infection by 23% in-vitro [26].
Our finding that L. jensenii can induce NF-κB activa-
tion and at the same time maintain low levels of
inflammation-associated proteins has important implica-
tions for its potential use as a vaginal probiotic or
biotherapeutic. NF-κB is a major transcription factor
that plays a key role in inflammatory disease and upre-
gulates a myriad of inflammation-associated genes in-
cluding those studied here [52]. At the same time NF-κB
participates in its own negative feedback loop promoting
the resolution of inflammation in-vivo [53]. Thus, the
net effect of NF-κB activation depends on the cell and
tissue context, the interplay of a number of intra- and
Figure 4 Cytokine profiles induced by bacteria or synthetic TLR2/6 ligand in cervicovaginal colonized epithelial model. Similar IL-8 levels
measured in supernatants derived from primary and immortalized epithelial cells cultured with L. jensenii 1153–1666, 3666, gfp bioengineered
and L. jensenii 1153 wild type (WT) strains or MALP-2 50 nM as a positive control. (Figure 4a) Two independent experiments with (VEC-100
™)
primary ectocervical originated tissue. (Figure 4b) Vaginal (Vk2/E6E7) and endocervical (End1/E6E7) epithelial colonized cells in one representative
of three experiments. Bars represent mean and SEM from duplicate cultures. *** P<0.001 different from medium control,
+++ P<0.001 different
from L. jensenii WT.
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signal. It has been previously shown that some lactoba-
cillus species (L. crispatus and L. acidophilus) can cause
NF-κB activation and yet maintain low levels of IL-8 and
RANTES [20]. Another study showed that L. jensenii
can suppress IL-8 induced by TLR ligands [54]. Interest-
ingly, a non-vaginal lactobacillus species (L. kefiranofa-
ciens) induced production of MIP-3α [55] and other
vaginal bacteria, associated with bacterial vaginosis e.g.
P. bivia and A. vaginae induced simultaneous NF-κB ac-
tivation and upregulation of inflammatory proteins in
contrast to vaginal L. crispatus and L. acidophilus, which
maintained low levels of proinflammatory proteins in
the vaginal colonization context [20]. We now demon-
strate for the first time using an expanded panel of
innate immunity mediators that this immuno-modulatory
phenomenon is also true for the L. jensenii isolate 1153
and its bioengineered derivatives. The results of our study
agree with clinical observations showing an association of
vaginal lactobacilli with relatively low levels of pro-
inflammatory mediators in-vivo [56-58]. Furthermore, the
results from our in-vitro model are in agreement with
findings generated in a macaque model of SHIV infection
[26]. Vaginal levels of IL-6, IL-8, IL-1β and IL-1RA were
not different between macaques with no lactobacilli, those
colonized with lactobacillus indigenous for the macaque
and those colonized with mCV-N expressing L. jensenii
1153–1666 [26]. Other commensal bacteria have also been
shown to downregulate inflammatory responses. For ex-
ample, H. pylori downregulated IL-8, MIP-3α and other
Figure 5 Absence of a pro-inflammatory cytokine response in L. jensenii colonized epithelial model. (Figure 5a) TNF-α, (Figure 5b) IL-6,
(Figure 5c) IL-1α, (Figure 5d) IL-1RA cytokine levels measured in supernatants from vaginal (Vk2/E6E7) epithelium cultured for 24 h with L. jensenii
1153–1666, 3666, and gfp bioengineered strains and L. jensenii 1153 wild (WT) strain or MALP-2 (50 nM) as a positive control. Bars represent mean
and SEM from duplicate and triplicate cultures in two independent experiments. *** P<0.001,* P<0.05 different from medium control,
+++ P<0.001
different from L. jensenii 1153 WT.
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http://www.biomedcentral.com/1471-2180/13/4chemokines through inducing microRNA expression in
host epithelial cells [59]. Further research is required to
determine the molecular mechanisms, by which vaginal L.
jensenii, L. crispatus and L. acidohilus tune the host innate
immune responses to avoid proinflammatory protein pro-
duction in the presence of a potent NF-κB activation.
The innate immunity mediators assessed here (TNF-α,
IL-1α, IL-1RA, IL-6, ICAM-1, IL-8, RANTES, MIP-3α
and SLPI) are known as indicators of mucosal toxicity,
and inflammation and have been used and recom-
mended for microbicide safety evaluation [32,35,60]. In
contrast to IL-1RA, which displays anti-inflammatory
properties [35,61], the pro-inflammatory cytokines
IL-1α, TNF-α, IL-6 and IL-8 can activate HIV viral repli-
cation in infected cells [62-66]. Similarly vaginal inflam-
mation increases the risk of HIV transmission by
increasing the number of host cells at the site of infec-
tion [35,67,68]. IL-8 is also involved in the recruitment
of innate immune cells, neutrophils and CD4 positive
T-cells to the site of infection [32,64,69]. MIP-3α is a
chemokine recruiting dendritic cells and along with
RANTES, a chemokine for T cells, is known to play a
role in the early recruitment of HIV target cells [70,71].
Thus, the lack of upregulation of these proinflammatory
mediators by the cervicovaginal epithelial cells is a
desired safety feature of the mCV-N expressing L. jensenii
strain. Concerns about the safety of CV-N in the absence
of lactobacillus have been raised by Huskens et al. [72]
showing that administration of CV-N to pre-stimulated
PBMC induced proinflammatory cytokine upregulation
and it also had in-vitro mitogenic activity. It is important
to clarify that the study by Huskens et al. is of limited rele-
vance to the clinical application of the mCV-N-expressing
lactobacilli for several reasons: 1) the mCV-N is a genetic-
ally modified stable monomeric derivative of the natural
cyanobacterium-produced CV-N protein referred to in
that older study, 2) Huskens et al. seemed to have used
E. coli expressed CV-N protein; however, they don’ta d -
dress steps taken to eliminate or control for endotoxin
contamination in their experiments. In contrast, in our
study mCV-N is expressed in the context of lactobacillus
which lacks endotoxin.
IL-1α, IL-1RA and SLPI are stored in the epithelial cell
and released upon membrane damage [35,61,73]. The
fact that none of the L. jensenii strains caused significant
increase in these mediators suggests preserved mem-
brane integrity in addition to lack of immunotoxicity. A
decrease in SLPI levels is also often associated with an
increased risk of HIV infection [74,75]. This in addition
to the lack of apoptosis assessed by caspase-3 levels sug-
gests that L. jensenii is capable of colonizing and self-
sustaining the human vaginal epithelia without cellular
toxicity. In this model L. jensenii produced full-length
biologically active mCV-N within the epithelial context.
mCV-N did not compromise cell viability or elicit an
immuno-inflammatory response when tested in both
rabbits and macaques [23,76].
This study confirmed the ability of bioengineered L.
jensenii strains to reproducibly colonize the cervicovaginal
epithelial model and to maintain anti-HIV expression of
functional peptides in-vitro without the induction of a
significant change in inflammation associated proteins.
The ability for endogenous lactobacilli to colonize and es-
tablish dominance in the vaginal microenvironment has
been previously investigated. Lactobacillus isolates were
successfully introduced intravaginally as a probiotic
against BV and urinary tract infections in women [77,78].
In a study conducted by Hemmerling et al. L. crispatus
colonized BV infected women 61-78% of the time [79].
We found all L. jensenii strains including the mCV-N
Figure 6 L. jensenii consistently colonize epithelial model over a 72 h time period in the absence of IL-8 upregulation. Vaginal epithelial
colonization of L. jensenii 1153–1666, 2666, 3666, 1646 and gfp bioengineered strains compared with L. jensenii 1153 wild type (WT) strain at the
end of 24 h, 48 h, and 72 h, time points. (Figure 6a) Colony forming units (CFU) enumerated from lysates harvested at the end of each 24 h
incubation time period. (Figure 6b) Consistent IL-8 profile maintained over time measured in the corresponding supernatants collected at the
end of each 24 h incubation. Bars represent mean and SEM from duplicate cultures in four independent experiments. ***P<0.001, **P<0.001
different from medium control,
+++P<0.001,
+P<0.001 different from L. jensenii WT.
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http://www.biomedcentral.com/1471-2180/13/4Figure 7 Bacterial colonization by wild type and bioengineered L. jensenii sustained for 72 h does not alter levels of inflammation-
associated proteins. Levels of immune mediators measured in cell culture supernatants by MSD multiplex after colonization of vaginal epithelial
cells to by L. jensenii 1153 and modified Cyanovirin-N (mCV-N) expressing 1153–1666 for 72 h or after 24 h exposure to MALP-2 and subsequent
change of medium at 24 h, 48 h, and 72 h. Bars represent mean and SEM from duplicate cultures in four independent experiments. ***P<0.001,
** P<0.01, * P<0.05 different from medium control,
+++P<0.001,
++P<0.01,
+P<0.05 different from L. jensenii WT.
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http://www.biomedcentral.com/1471-2180/13/4expressing L. jensenii (1153–1666) capable of reproducibly
and stably colonizing the human cervicovaginal epithelial
cells over a 72 h period without significant perturbations
to innate immune barrier parameters while abundantly
expressing mCV-N detectable by both Western blot and
the functional gp120 assay. The stable colonization
mCV-N expressing L. jensenii 1153–1666 strain and the
stability and anti-HIV activity of the mCV-N protein have
been confirmed in a mouse model over a period of six
days [15] and in the Rhesus macaque for six weeks post
inoculation [26], where it reduced SHIV infection by 63%
in a repeated challenge model, without altering mar-
kers associated with mucosal barrier function. Taken
together these in-vivo findings provide validation of our
in-vitro model.
The bioengineered mCV-N, similarly to the natural
protein, is stable at a broad pH range from 4–8.2 [15,23].
This wide pH stability spectrum encompasses both the
acidic pH generated by lactic acid producing bacteria and
the slightly more alkaline pH introduced to the vaginal
environment with seminal fluid. The natural and modified
CV-N molecules are also resistant to thermal and chem-
ical denaturation, which would allow it to be produced
and stored in a variety of environmental conditions
[15,23]. These attributes render mCV-N to be a promising
microbicide candidate.
In this proof-of-concept in-vitro model, the bioengi-
neered L. jensenii did not differ from the wild type pa-
rental strain in term of epithelial colonization capacity
and did not induce a pro-inflammatory profile in the
Figure 8 Epithelial colonized L. jensenii preserve potent anti-HIV properties. Western blot from 24 h sterile supernatants collected from L.
jensenii-colonized vaginal (Vk2/E6E7) and endocervical (End1E6E7) epithelial cells demonstrate consistent preservation of modified Cyanovirin-N
(mCV-N) expression in mCV-N producing strains. (Figure 8a) mCV-N producing bioengineered strains (L. jensenii 1153–1666, 2666 and 3666)
located in lanes #2, 3 and 4 are contrasted to L. jensenii 1153 WT in lane #1, the β-glucuronidase expressing strain L. jensenii 1153–1646 in lane #5,
MALP-2 control in lane #6, and medium control in lane #7. (Figure 8b) A mCV-N standard in lane #1 is compared to the mCV-N producing L.
jensenii strains: L. jensenii 1153–1666 and 3666 in lanes #4 and #5 in contrast to the green florescent protein expressing strain L. jensenii 1153-gfp
in lane #6, MALP-2 in lane #3 and medium control in lane #2. (Figure 8c) No loss to filtration is observed in western blot analyses of mCV-N
before and after spiking one ml of media with one μg mCV-N. (Figure 8d) gp120 binding activity in one representative mCV-N producing L.
jensenii 1153–1666 strain detected by a gp120 binding assay in sterile supernatants collected from 24 h L. jensenii colonized vaginal (Vk2/E6E7)
epithelial culture. Data are from one representing three independent experiments.
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http://www.biomedcentral.com/1471-2180/13/4human epithelial cell context. Thus, our in-vitro findings
along with in-vivo studies performed in the murine and
macaque model pave the way to further clinical safety
evaluations necessary to confirm the effects these bac-
teria would have when introduced into the human cervi-
covaginal environment and how it would affect other
endogenous microbiota in-vivo. There are many compo-
nents that are unique to the human vaginal environment
and therefore would be best investigated in-vivo i.e. indi-
genous bacterial biofilms, pH, mucosal immunoglobulins
and hormones, and vaginal practices that may modify
the effects of both the bioengineered bacteria and the
activity of mCV-N peptide.
Conclusion
Our in-vitro human vaginal colonization model produced
consistent results, validated by their agreement with fin-
dings from the in-vivo macaque model. Because of its re-
producibility and low cost, the in-vitro colonization model
can be used for high throughput preclinical screening and
side-by-side comparison of multiple bacterial strains,
bioengineered derivatives and probiotic candidates to
select those with best homeostatic properties. In support
of our hypothesis, we were able to compare microbiota-
epithelial interactions of multiple L. jensenii WT and
bioengineered strains in a reproducible manner. The
bioengineered L. jensenii derivatives were able to deliver a
bioactive anti-HIV peptide without inducing cellular tox-
icity or alterations in levels of pro-inflammatory cytokines
and protective mucosal immune mediators e.g. SLPI or
IL-1RA. Our pre-clinical safety data in combination with
the results from the macaque model provide support for
future clinical evaluations of the bioengineered L. jensenii
bacteria as an anti-HIV microbicide.
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